Online inquiry

IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7334MR)

This product GTTS-WQ7334MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VTCN1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001253849.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 79679
UniProt ID Q7Z7D3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7334MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15159MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ13544MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ3861MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ4094MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ14302MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ6351MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ5924MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CK-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW